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pt received April 12, 2013his study sought to evaluate the prevalence and signiﬁcance of ventricular arrhythmia (VA) and the role of an
implantable cardioverter-deﬁbrillator (ICD) in patients supported by a continuous-ﬂow left ventricular assist device
(CF-LVAD).Background VAs are common in patients supported by CF-LVADs but prospective data to support the routine use of ICDs in these
patients are lacking.Methods All patients supported by long-term CF-LVAD receiving care at our institution were enrolled. The ICDs were
interrogated at baseline and throughout prospective follow-up. The VA was deﬁned as ventricular
tachycardia/ﬁbrillation lasting >30 s or effectively terminated by appropriate ICD tachytherapy. The primary
outcome was the occurrence of VA >30 days after CF-LVAD implantation.Results Ninety-four patients were enrolled; 77 had an ICD and 17 did not. Five patients with an ICD had it deactivated
or a depleted battery not replaced during the study. Twenty-two patients had a VA >30 days after LVAD
implantation. Pre-operative VA was the major predictor of post-operative arrhythmia. Absence of pre-operative
VA conferred a low risk of post-operative VA (4.0% vs. 45.5%; p < 0.001). No patients discharged from the
hospital without an ICD after CF-LVAD implantation died during 276.2 months of follow-up (mean time without
ICD, 12.7  12.3 months).Conclusions Patients with pre-operative VA are at risk of recurrent VA while on CF-LVAD support and should have active ICD
therapy to minimize sustained VA. Patients without pre-operative VA are at low risk and may not need active ICD
therapy. (J Am Coll Cardiol 2013;61:2542–50) ª 2013 by the American College of Cardiology FoundationThe role of the implantable cardioverter-deﬁbrillator (ICD) for
primary prevention of sudden cardiac death in patients with
heart failure has been well established in multiple large
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confer a mortality beneﬁt in patients with heart failure and
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; accepted April 29, 2013.support devices have assumed an important role in the treatment
of patients with class IV symptoms either as a bridge to cardiac
transplantation (BTT) or as destination therapy (DT).
Although ventricular arrhythmia (VA) is often a lethal
event in patients with heart failure, the presence of contin-
uous-ﬂow left ventricular assist devices (CF-LVAD) may
alter the impact of VAs for these patients. For patients
supported by LVADs, VAs are common, and numerous
studies have demonstrated that appropriate tachytherapies
are delivered by ICDs in 22% to 52% of patients with
LVADs (3–10). Some investigators have suggested that
LVADs are arrhythmogenic, either by introducing new areas
of scar or by altering gene expression of ion channels possibly
involved in arrythmogenesis (3,4). Although VAs may
be common, there have been reports of patients surviving
after hoursdand in extreme cases, monthsdof ventricular
ﬁbrillation (VF) (11–17).
Abbreviations
and Acronyms
BTT = bridge to
transplantation
CF-LVAD = continuous-ﬂow
left ventricular assist device
DT = destination therapy
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2543Prospective data deﬁning the role of ICDs in patients
with continuous-ﬂow LVADs are lacking. Accordingly,
we sought to characterize the prevalence, risk factors, and
signiﬁcance of VAs in patients with long-term CF-
LVADs to determine whether concomitant ICD therapy
is necessary for all patients receiving long-term mechanical
support.ICD = implantable
cardioverter-deﬁbrillator
LVAD = left ventricular
assist device
VA = ventricular arrhythmia
VF = ventricular ﬁbrillation
VT = ventricular tachycardiaMethods
This study was approved by the institutional review board of
the Columbia University Medical Center. All patients 18
years of age or older with a long-term CF-LVAD presenting
to our institution between January 1, 2012, and October 1,
2012, were enrolled and followed up prospectively. The
primary outcome was the occurrence of “late” VAs (>30 daysFigure 1 12-Lead ECGs From the ED and Clinic
(A) This 12-lead electrocardiogram (ECG) was obtained in the emergency department (ED
months after continuous-ﬂow left ventricular assist device (CF-LVAD) implantation who pres
ICD insertion for secondary prevention. (B) This 12-lead ECG was obtained in the clinic fro
ventricular failure with peripheral edema, renal failure, and low pulsatility index on LVAD int
began 2 weeks before presentation.post-operatively) after LVAD
implantation. Any VAs occurr-
ing within 30 days of LVAD
implantation were excluded be-
cause of the likelihood that they
would occur in a hospitalized
setting and often in the presence
of intravenous vasoactive thera-
pies. Secondary outcomes were
all-cause mortality and catheter
ablation of VA. Deaths were
classiﬁed as “cardiac” when a de-
ﬁnitive cause of death related to
a cardiovascular event could be
identiﬁed, “noncardiac” when the
cause of death identiﬁed did not) from a 66-year-old man without an implantable cardioverter-deﬁbrillator (ICD) and 3
ented with 4 h of dizziness. He was externally cardioverted and underwent successful
m a 73-year-old man 1 year after CF-LVAD implantation who was found to have right
errogation. The ICD interrogation revealed that this episode of ventricular tachycardia
Table 1 Baseline Demographics of Patients
Variable
All
(n ¼ 94)
With ICD
(n ¼ 77)
Without ICD
(n ¼ 17) p Value
Age, yrs 62.2  12.0
66.0 (50.3–72.0)
63.1  11.8
66.0 (54.0–73.0)
58.1  12.3
56.0 (48.0–69.0)
0.11
Male 85.1 (80) 90.9 (70) 58.8 (10) 0.003
Cardiomyopathy, ischemic 52.1 (49) 50.6 (39) 58.8 (10) 0.60
Indication, BTT 48.9 (46) 48.1 (37) 52.9 (9) 0.79
INTERMACS proﬁle, 1 or 2 71.3 (67) 67.5 (52) 88.2 (15) 0.14
RV failure after LVAD 43.6 (41) 45.5 (35) 35.3 (6) 0.59
Disease duration >3 months 86.2 (81) 97.4 (75) 35.3 (6) <0.001
LVEF, % 17.2  5.3
17.5 (12.5–20.0)
16.8  5.0
17.5 (12.5–20.0)
18.8  6.4
17.5 (15.0–22.5)
0.28
LVEDD, cm 6.8  1.0
6.8 (6.1–7.5)
7.0  0.9
6.9 (6.3–7.6)
5.8  1.0
5.8 (4.9–6.2)
<0.001
Beta-blocker 94.7 (89) 96.1 (74) 88.2 (15) 0.22
Antiarrhythmic medication 40.4 (38) 37.7 (29) 52.9 (9) 0.28
Values are mean  SD with median (interquartile range) or % (n).
BTT ¼ bridge to transplant; ICD ¼ implantable cardioverter-deﬁbrillator; INTERMACS ¼ Interagency Registry for Mechanical Assisted Circulatory
Support; LVAD ¼ left ventricular assist device; LVEDD ¼ left ventricular end-diastolic dimension; LVEF ¼ left ventricular ejection fraction; RV ¼ right
ventricle.
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2544relate to the cardiovascular system, or “indeterminate” when
the cause of death was unknown. Whenever possible, ICDs
were interrogated at the time of death to ascertain whether VA
might have been the cause of death.
Ventricular arrhythmias. A VA was deﬁned as ventricular
tachyarrhythmia (ventricular tachycardia [VT] or ventricular
ﬁbrillation [VF]) that received appropriate therapy (anti-
tachycardia pacing or shock) from an ICD or was sustained
for >30 s in the absence of effective treatment. Intracardiac
electrograms, telemetry tracings, or electrocardiograms were
obtained for each episode and reviewed by an electrophysi-
ologist. Device detection thresholds and treatment algo-
rithms were individualized for each patient. The VAs were
divided into those occurring early (within 30 days after
LVAD implant surgery) or late (occurring >30 days after
surgery).
Enrollment and follow-up. Patients with an ICD and
patients without an ICD were enrolled. At our institution,
patients who undergo CF-LVAD implantation without an
ICD do not routinely have an ICD inserted before
discharge. After the informed consent process, a list of active
medications, current LVAD settings, and demographicTable 2 Electrophysiologic History of Patients
Variable
All
(n ¼ 94)
Antiarrhythmic drug pre-operatively 42.6 (40)
Pre-LVAD VA
1 month 21.3 (20)
3 months 25.5 (24)
6 months 36.2 (34)
Any 46.8 (44)
VT ablation 7.4 (7)
CRT device 51.1 (48)
Atrial arrhythmia 68.1 (64)
Values are % (n) or mean  SD with median (interquartile range).
CRT ¼ cardiac resynchronization therapy; VA ¼ ventricular arrhythmia; VTinformation were recorded. Next, patients with ICDs
underwent device interrogation. Information collected
included the tachyarrhythmia settings and details for each
VA event stored within the device that resulted in
therapy. For patients who already had an LVAD at the
time of enrollment, VAs that had occurred before the
enrollment period were identiﬁed by the initial ICD
interrogation and were included in the analysis with those
occurring during study follow-up. After enrollment,
patients were followed up prospectively for the occurrence
of VAs.
Routine evaluation of patients presenting with VAs
included a transthoracic echocardiogram to exclude a
“suction” event, deﬁned as obstruction of the inﬂow cannula
by myocardium, which frequently results in a tachyar-
rhythmia. All patients without ICDs underwent electrocar-
diography or telemetry monitoring whenever they reported
symptoms suggestive of VAs (e.g., dizziness, palpitations) or
manifested signs of right ventricular failure.
Statistical analysis. Data were collected using Excel soft-
ware (Microsoft Corp., Redmond, Washington). All data
were analyzed using R version 2.15.2. Categorical valuesWith ICD
(n ¼ 77)
Without ICD
(n ¼ 17) p Value
42.9 (33) 41.2 (7) 1.00
24.7 (19) 5.9 (1) 0.11
31.2 (24) 0 (0) 0.005
44.2 (34) 0 (0) <0.001
55.8 (43) 5.9 (1) <0.001
9.1 (7) 0 (0) 0.34
62.3 (48) 0 (0) <0.001
67.5 (52) 70.6 (12) 1.00
¼ ventricular tachyarrhythmia; other abbreviations as in Table 1.
Figure 2 Distribution of Late Post-Operative VA
Of the 22 patients who experienced post-operative (Post-Op) ventricular arrhythmia (VA), 9 patients had only 1 VA and 4 patients had 5 or more.
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2545are presented as percentages and continuous variable as
mean  SD and medians with interquartile ranges. Fisher’s
exact test was used to examine the association between
binary variables. For comparison of continuous variables
between groups, the Wilcoxon rank-sum test was used. For
the survival analysis, the Mantel-Haenszel test was used to
compare survival curves between groups. For multivariate
analysis, Cox regression models were used. A p value <0.05
was considered statistically signiﬁcant.Results
Ninety-four patients were enrolled; 77 had an ICD and 17
did not. One patient without an ICD at the time of LVAD
implantation underwent ICD insertion after experiencingTable 3 Univariate Analysis of Risk Factors for P
Variable
With VA
(n ¼ 22)
Age, yrs 62.4  13.8
63.5 (51.3–73.8)
Male 95.5 (21)
Cardiomyopathy, ischemic 54.5 (12)
INTERMACS class 1 or 2 68.2 (15)
Indication, BTT 50.0 (11)
RV failure post-VAD 54.5 (12)
LVEF, % 15.7  6.0
12.5 (12.5–17.5)
LVEDD, cm 7.1  1.0
7.2 (6.6–7.7)
Any VA pre-LVAD 90.9 (20)
VT ablation 18.2 (4)
Beta-blocker 90.9 (20)
Antiarrhythmic medication 54.5 (12)
Values are mean  SD with median (interquartile range) or % (n).
Abbreviations as in Tables 1 and 2.sustained VF after hospital discharge (Fig. 1A). None of the
remaining 16 patients without an ICD underwent “primary
prevention” insertion of an ICD. In addition, 5 patients had
their ICD either deactivated or did not have a depleted
generator changed after the device had reached end of
life. Total time with a deactivated ICD was 40.1 patient-
months.
The baseline characteristics of patients with and patients
without an ICD are presented in Tables 1 and 2. Overall,
85.1% (n ¼ 80) were men, 52.1% (n ¼ 49) had an ischemic
cardiomyopathy, and 48.9% (n ¼ 46) were implanted as
BTT. The average age was 62.2  12.0 years. Seven (7.4%)
had undergone catheter ablation for VT before surgery, and
44 (46.8%) had had at least 1 VA before surgery. Forty
patients (42.6%) were receiving an antiarrhythmic drug atost-Operative VA
Without VA
(n ¼ 72) p Value
62.2  11.6
66.0 (50.8–71.3)
0.69
81.9 (59) 0.18
51.4 (37) 0.81
72.2 (52) 0.79
48.6 (35) 1.00
40.3 (29) 0.33
17.7  5.0
17.5 (12.5–20.6)
0.04
6.7  1.0
6.7 (6.1–7.3)
0.06
33.3 (24) <0.001
4.2 (3) 0.0497
95.8 (69) 0.33
36.1 (26) 0.14
Table 5
Risk of Post-Operative VA With Respect to
Pre-Operative VA
Post-LVAD VA* No Post-LVAD-VA
Pre-LVAD VA 45.5% 54.5%
No pre-LVAD VA 4.0% 96.0%
*p < 0.001.
Abbreviations as in Tables 1 and 2.
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2546the time of LVAD implantation. Eighty-nine (94.7%)
patients were taking a beta-blocker. The mean left ventric-
ular end-diastolic dimension was 6.8  1.0 cm and the mean
left ventricular ejection fraction was 17.2  5.3%. Patients
without an ICD were more often women (41.2% vs. 9.1%;
p ¼ 0.003), were more likely to have had <3 months of
disease duration (64.7% vs. 2.6%; p < 0.001), and were
more likely to have a smaller left ventricular end-diastolic
dimension (5.8  1.0 cm vs. 7.0  0.9 cm; p < 0.001).
There were no differences in the number of patients taking
beta-blockers or antiarrhythmic medications in the 2 groups
during the study period.
Follow-up time. Sixty-two patients (66.0%) had under-
gone CF-LVAD implantation before the enrollment period.
Total time supported by CF-LVAD in patients with an
active ICD was 969.1 patient-months, and prospective
follow-up time totaled 281.0 patient-months. Total time
supported by CF-LVAD for patients without an active ICD
was 276.2 patient-months (mean 12.7  12.3 months), and
prospective follow-up time totaled 139.6 patient-months.
Prevalence of VA. The prevalence of VAs occurring within
the ﬁrst 30 days post-operatively was 20.2%; the prevalence
occurring >30 days after LVAD implantation was 23.4%.
Excluding VAs that occurred within the ﬁrst 30 days,
22 (23.4%) patients had 98 VAs for an event rate of 1.2 VAs
per patient-year. Four patients had 5 or more late VAs.
Among patients without an active ICD, the prevalence of
VAs occurring >30 days post-operatively was 4.0%. The
distribution of post-operative VAs is shown in Figure 2.
Predictors of late VA. Predictors of late VAs among
patients with an ICD are shown in Tables 3 and 4. In
a multivariate analysis, the only independent predictor of the
occurrence of late post-operative VAs was the presence of
VA before LVAD implantation. Age, sex, and the
INTERMACS (Interagency Registry for Mechanical
Assisted Circulatory Support) proﬁle were not statistically
different between patients with and patients without late
VAs. Similarly, the etiology of the patient’s cardiomyopathy,
baseline left ventricular function, and left ventricular
end-diastolic dimension were not independent predictors of
post-operative VAs. Lastly, the occurrence of right ventric-
ular failure in the post-operative period was not predictive of
the occurrence of late VAs. The positive predictive value of
pre-operative VAs was 45.5%, and the negative predictive
value was 96.0% (Table 5). A time-to-event analysis for
freedom from post-operative VAs is shown in Figure 3.Table 4
Multivariate Cox Regression Model of
Risk Factors for Post-Operative VA
Variable HR 95% CI p Value
Male 4.0 0.5–33.0 0.2
LVEF 1.0 0.9–1.1 1.0
LVEDD 0.9 0.5–1.5 0.7
VA pre-LVAD 19.1 4.3–84.0 <0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.VA untreated by ICD. Six patients had sustained VAs that
were not immediately terminated (Table 6); of those, 5 had
ICDs and 1 did not. In 3 patients, attempts by the ICD to
cardiovert VT failed; 2 survived despite transformation to
sustained VF; and 1 died as a result of several weeks of
recurrent, intractable VT that ultimately led to right
ventricular failure and multisystem organ failure. In the
2 other instances where the arrhythmias were sustained
despite the presence of an ICD, the patients had VT in the
monitor-only zone: 1 at a rate of 160 beats/min and the
other at a rate of 170 beats/min (Fig. 1B). On device
interrogation, both of these arrhythmias had lasted for
2 weeks before clinical detection. The patient without an
ICD presented with dizziness for 4 h and was found to be in
VF. He was externally cardioverted and a secondary
prevention ICD was implanted (Fig. 1A).
All 6 patients who had a prolonged VA presented with
right ventricular failure and worsening renal function; 4 also
had worsening liver function test abnormalities. Except for
the single patient in this group who had <3 months of
disease duration pre-operatively, all had experienced 2 or
more VAs pre-operatively.Figure 3
Kaplan-Meier Analysis of Freedom From
VA Stratiﬁed by Pre-Operative VA
A history of pre-operative (Pre-Op) ventricular arrhythmia (VA) (red line) was
predictive of post-operative (Post-Op) VA. Solid line indicates no pre-operative VA.
Table 6 Prolonged Ventricular Arrhythmias
Patient # Age, Sex CHF Etiology Outcome
1 73, M Ischemic Presented with 2 weeks sustained VT with rate in monitor zone of ICD (see Fig. 1B)
2 74, M Ischemic Presented with 2 weeks sustained VT with rate in monitor zone of ICD; underwent VT ablation for recurrent sustained VT
3 49, M Nonischemic Syncope as a result of 12 h VF, which was unsuccessfully cardioverted by ICD
4 61, M Ischemic Required external cardioversion after 30 min of asymptomatic VF unsuccessfully cardioverted by ICD
5 66, M Ischemic No ICD, presented with orthostasis in VF; cardioverted externally, underwent secondary prevention ICD implantation (see Fig. 1A)
6 51, M Nonischemic Died of recurrent, intractable VT despite ICD tachytherapies, multiple antiarrhythmic medications, and epicardial VT ablation
CHF ¼ congestive heart failure; VF ¼ ventricular ﬁbrillation; other abbreviations as in Tables 1 and 2.
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2547VA requiring ablation. Three (3.2%) patients underwent
catheter ablation for VT after LVAD implantation. Of
these, 2 procedures were performed endocardially and 1
was performed epicardially. A total of 8 VTs were
inducible, and 5 were successfully ablated; 2 patients had 4
inducible VTs each, and 1 patient had none. Of the 2
patients who underwent successful ablation, both had
subsequent VAs. One ultimately died of intractable VT
with subsequent right ventricular failure (detailed in
preceding text), and the other had a reduction in the
frequency of VAs.
Outcomes. During the follow-up period, there were
7 deaths (Table 7). One death was cardiac, 4 were
noncardiac, and 2 were indeterminate. Two deaths occurred
in patients with ICDs that were no longer active; 1 was
secondary to persistent Enterococcus faecium infection, and
the other was indeterminate. The remaining 5 deaths were
of patients with an active ICD; causes of death were right
ventricular failure secondary to weeks of intractable VA
(detailed in preceding text), intracranial hemorrhage,
Clostridium perfringens infection, hypoxemic respiratory
failure, and indeterminate. There was no difference in
survival when patients were stratiﬁed by the presence or
absence of active ICD therapy (Fig. 4). There were no
deaths among patients who were discharged after LVAD
implantation without an ICD. The overall mortality was
6.7% per year, and the overall mortality from cardiac or
indeterminate causes was 2.9% per year.
Of 35 patients with an LVAD as DT and an active ICD,
91.4% (n ¼ 32) remain on support, 5.7% (n ¼ 2) died, and
2.9% (n ¼ 1) had the LVAD explanted during the study
period. Of 37 patients with an LVAD as BTT and an activeTable 7 Causes of Death
Cause of Death
Active ICD
(n ¼ 5)
No Active ICD
(n ¼ 2)
Cardiac 1 0
Arrhythmic 1 0
Nonarrhythmic 0 0
Noncardiac 3 1
Infection 1 1
Intracranial bleeding 1 0
Respiratory failure 1 0
Indeterminate 1 1
ICD ¼ implantable cardioverter-deﬁbrillator.ICD, 54.1% (n ¼ 20) remain on support, 37.8% (n ¼ 14)
underwent orthotopic heart transplant (OHT), and 8.1%
(n ¼ 3) died during the study period.
Of 13 patients with an LVAD as DT and without an
active ICD, 84.6% (n ¼ 11) remain on support and 15.4%
(n ¼ 2) died. Finally, of 9 patients with an LVAD as BTT
and without an active ICD, 55.6% (n ¼ 5) remain on
support, 33.3% (n ¼ 3) have undergone OHT, and 11.1%
(n ¼ 1) had the LVAD explanted.
Discussion
In the current study, we aimed to determine the prevalence
and clinical signiﬁcance of ventricular arrhythmias after
LVAD implantation. Furthermore, we sought to determine
the role of the ICD in this patient population. Our principal
ﬁndings are as follows: 1) VAs were common among
patients with long-term CF-LVADs. 2) VAs are usually not
life-threatening during CF-LVAD support, although
a subset of patients has signiﬁcant arrhythmic morbidity
and represents those who may beneﬁt from aggressive
antiarrhythmic therapies including pharmacotherapy, ICDFigure 4
Kaplan-Meier Survival Analysis in Patients Stratiﬁed
by ICD Therapy
There was no difference in survival between patients with an active implantable
cardioverter-deﬁbrillator (ICD) (solid line) and patients without an active ICD
(red line).
Garan et al. JACC Vol. 61, No. 25, 2013
Ventricular Arrhythmias and ICDs in LVAD Patients June 25, 2013:2542–50
2548therapies, and catheter ablation. 3) Pre-operative VAs were
the major predictor of late post-operative VAs in this
population, and the risk of developing de novo VAs after
LVAD implantation is low. 4) There was no difference in
mortality between patients with and patients without active
ICDs, as CF-LVADs appear to provide enough hemody-
namic support to prevent sudden arrhythmic death in
patients without an ICD.
To our knowledge, this is the ﬁrst prospective analysis of
the clinical impact of VAs in patients supported by long-
term CF-LVADs. Increasing numbers of patients are
undergoing implantation of long-term mechanical circula-
tory support devices as DT and BTT. As patients with CF-
LVADs are supported for increasing duration, the following
questions have arisen: 1) Should ICDs be implanted in
patients who undergo CF-LVAD implantation without
a pre-existing device; and 2) should generators be changed
when depleted in patients with CF-LVADs and an ICD?
In the largest retrospective study to date, Cantillon
et al. (5) demonstrated that the presence of an ICD was
associated with improved survival in patients with
LVADs. However, this analysis included mostly pulsatile
devices. Pulsatile ﬂow pumps are ﬁlled by contribution
from the native heart, relying on systolic ﬁlling, and in this
way are pre-load sensitive. In contrast, continuous-ﬂow
pumps ﬁll actively in both systole and diastole and are less
sensitive to pre-load and contribution from the native
heart. Therefore, results from the pulsatile pump era
may not apply to today’s patients with contemporary
continuous-ﬂow pumps.
Because of a lack of prospective data supporting their use,
ICDs are not routinely inserted in patients undergoing
CF-LVAD implantation at our center. Hence, our analysis
includes 17 patients supported by CF-LVAD who were
discharged without an ICD. Not surprisingly, these patientsFigure 5 Treatment Strategy for Managing ICD Therapy in Patients S
The decision to insert an implantable cardioverter-deﬁbrillator (ICD) in a patient with a cont
generator is dependent on the presence or absence of pre-operative ventricular arrhythmhad shorter disease durationdoften undergoing CF-LVAD
implantation during their index admission for heart
failuredand less ventricular dilation than patients who
had an ICD at the time of CF-LVAD implantation.
Importantly, none of the patients discharged from the
hospital without an ICD after their index admission for
CF-LVAD implantation died during the study period.
During >400 patient-months of prospective follow-up
time, we identiﬁed pre-operative VA as the lone indepen-
dent predictor of post-operative VAs. Neither type of cardio-
myopathy nor degree of ventricular dilation was predictive of
late VAs. Finally, right ventricular failure was common among
our cohort but it did not predict the occurrence of post-
operative VAs, although patients with prolonged ventricular
tachyarrhythmias uniformly presented with right ventricular
failure.
It is difﬁcult to assess the impact of VAs when they
are treated effectivelydand often without the patient’s
awarenessdby an ICD. In our study, a number of these events
were prolonged and allowed us to observe the consequences of
untreated VTs in the presence of a CF-LVAD. Although
ICDs may prevent adverse sequelae of sustained VAs in
a subset of patients (e.g., right ventricular failure, renal failure),
they do not appear to confer survival beneﬁt through
prevention of sudden cardiac death for this population as they
do for patients with advanced heart failure not supported
by LVADs, for CF-LVADs seem to prevent complete
hemodynamic collapse in the setting of VA.
Implementation of ICD therapy is not without risk. The
incidence of ICD infection appears to be rising and may be
as high as 7% in some reports (18). Furthermore, ICD
shocks have been associated with decreased quality of life
(19). With these potential risks in mind, we believe our data
support a patient-speciﬁc approach to arrhythmia manage-
ment in the LVAD population. Therefore, our center hasupported by CF-LVAD
inuous-ﬂow left ventricular assist device (CF-LVAD) but no ICD or to replace a depleted
ia (VA).
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2549adopted the following strategy (Fig. 5): 1) Patients without
pre-operative VAs do not need a primary prevention ICD
placed if they do not have a VA at the time of CF-LVAD
implantation; devices may be placed in the event of
VAs occurring de novo after CF-LVAD implantation. 2)
Patients with pre-operative VAs should have active ICD
therapy maintained to prevent the adverse sequelae of
sustained arrhythmias. 3) Patients without pre- or post-
operative VAs and an ICD with a depleted generator do
not need it replaced. Furthermore, deactivation of the ICD
should be performed for these patients when the device
reaches end of life to avoid the risk of device malfunction.
We believe such an approach to the question of ICD
therapy for patients with CF-LVADs warrants further
evaluation in a larger, multicenter prospective study. In
addition, it must be noted that this strategy does not take
into account the need for cardiac pacing or the potential
effects of cardiac resynchronization therapy. Whether
cardiac resynchronization therapy conveys a survival beneﬁt
or improved functional capacity in patients supported by
long-term CF-LVAD is entirely unknown and warrants
prospective evaluation. Until we are able to answer this
question, however, we will continue to recommend reac-
tivation of whatever pre-operative pacing settings the patient
had after CF-LVAD implantation.
Lastly, current practice is to implant ICDs in patients with
heart failure and refractory VAs. Our data indicate that
patients with a higher burden of pre-operative VAs were at
risk for having more post-operative VAs. Such arrhythmias
may put them at risk for the development or worsening of
right ventricular failure as well as recurrent shocks. Therefore,
for patients with ICDs at the time of CF-LVAD implan-
tation, we believe arrhythmia burden should be carefully
evaluated by device interrogation before the implementation
of mechanical circulatory support. That will allow patients at
high risk of post-operative VAs to be identiﬁed so that
interventions aimed at minimizing the risk of recurrent VAs,
including antiarrhythmic medication use, catheter ablation,
and even biventricular support, may be considered.
Study limitations. Our study represents a single-center
experience. The ICD therapy was not randomized, and
there was no standardization of ICD programming. Patients
with more aggressive tachytherapy settings might have had
higher rates of appropriately delivered tachytherapies that
would inﬂate their risk of VA. In addition, as patients
without ICDs were monitored clinically for evidence of
VAs, their risk might have been underestimated; VAs
lasting >30 s, then self-terminating, might have been
entirely undetected without an ICD to store or treat the
arrhythmia. It is important to note, however, that if they
occurred, such arrhythmias were of no clinical consequence.
As Oswald et al. (7) have suggested, less aggressive ICD
tachytherapy settings are appropriate for LVAD supported
patients given that the risk of sudden hemodynamic collapse
is obviated by mechanical support. Finally, while every effort
was made to identify all VAs, some might not have beenidentiﬁed if they were erased from the ICD at the time of
interrogation by another healthcare provider without docu-
mentation in the medical record.
Conclusions
Late ventricular arrhythmias are common after implantation
of a CF-LVAD. Pre-operative VAs predict post-operative
VAs, and patients without a history of arrhythmias are at
low risk of experiencing them de novo post-operatively.
Routine primary prevention implantation of ICDs or
generator changes for pre-existing devices are unnecessary
for patients without a history of VAs because CF-LVADs
provide a level of hemodynamic support that allows such
interventions to be performed according to a secondary
prevention strategy.Reprint requests and correspondence: Dr. Nir Uriel, Mechanical
Circulatory Support Program, Division of Cardiology, Columbia
University Medical Center/New York Presbyterian Hospital,
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